Eagle Pharmaceuticals

BELRAPZO

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Eagle Pharmaceuticals

Belrapzo HCPCS:

J9036

HCPCS Code Descriptor:

Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg

Category:

J Code

Belrapzo NDCs:

42367-0521-25, 42367-0520-25

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Belrapzo CPT Codes:

Potential CPT administration codes for Belrapzo can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

42367-0520-25

About Belrapzo:

BELRAPZO is an Oncology drug manufactured by Eagle Pharmaceuticals and administered via the Intravenous route of administration. The J Code: J9036 is aligned to the drug BELRAPZO.

Belrapzo is used to treat certain types of cancer and belongs to group of drugs known as alkylating agents. Belrapzo is manufactured by both Eagle Pharmaceuticals and Baxter Healthcare. There are two J Codes for Belrapzo: J9036 and J9306. Patient assistance programs for this medication can be found through Eagle Pharmaceuticals at the Eagle Can: Care & Access Network.

ACCESS PRICING AND MORE BY REGISTERING

J9036 Added Date:

July 1, 2019

J9036 Effective Date:

July 1, 2019

J9036 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Belrapzo billing and coding information.
Belrapzo patient assistance information can be found through Eagle Pharmaceuticals at the URL: https://belrapzo.com/reimbursement/
BELRAPZO prescribing information can be found at the link below:
Information regarding BELRAPZO’s side effects can be found at MedlinePlus